Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Rectal fistulae resulting from treatment with sorafenib and bevacizumab.

von Rosenvinge EC, Gopal LD, Heller T, Kohn EC, Yao MD.

Gastrointest Endosc. 2009 Dec;70(6):1246-7. doi: 10.1016/j.gie.2009.06.027. No abstract available.

PMID:
19683714
2.

Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.

Girardi F, Franceschi E, Brandes AA.

Oncologist. 2010;15(7):683-94. doi: 10.1634/theoncologist.2009-0235. Review.

3.

[Cutaneous side effects of antiangiogenic agents].

Robert C.

Bull Cancer. 2007 Jul;94 Spec No:S260-4. Review. French.

PMID:
17846013
4.

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

Kamba T, McDonald DM.

Br J Cancer. 2007 Jun 18;96(12):1788-95. Review.

5.

Vascular complications of selected cancer therapies.

Daher IN, Yeh ET.

Nat Clin Pract Cardiovasc Med. 2008 Dec;5(12):797-805. doi: 10.1038/ncpcardio1375. Review.

PMID:
18852710
6.

Sorafenib-induced erythema multiforme: three cases.

Namba M, Tsunemi Y, Kawashima M.

Eur J Dermatol. 2011 Nov-Dec;21(6):1015-6. doi: 10.1684/ejd.2011.1535. Review. No abstract available.

PMID:
21926043
7.

Sorafenib-induced premalignant and malignant skin lesions.

Williams VL, Cohen PR, Stewart DJ.

Int J Dermatol. 2011 Apr;50(4):396-402. doi: 10.1111/j.1365-4632.2010.04822.x. Review.

PMID:
21413947
8.

Nasal septal perforation from bevacizumab: a discussion of outcomes, management, and pharmacovigilance.

Ramiscal JA, Jatoi A.

Curr Oncol Rep. 2012 Aug;14(4):307-10. doi: 10.1007/s11912-012-0236-x. Review.

PMID:
22544558
9.

Types of colitis based on histology.

Sherid M, Ehrenpreis ED.

Dis Mon. 2011 Sep;57(9):457-89. doi: 10.1016/j.disamonth.2011.05.004. Review. No abstract available.

PMID:
21944389
10.

New drug toxicities in the onco-nephrology world.

Perazella MA, Izzedine H.

Kidney Int. 2015 May;87(5):909-17. doi: 10.1038/ki.2015.30. Review.

PMID:
25671763
Items per page

Supplemental Content

Support Center